PURPOSE:: The local control of inoperable @entity1149 ( @entity1149 ) using standard radiotherapy (RT) doses is inadequate. Dose escalation is a potential strategy to improve the local control for @entity1 with @entity1149 ; however, the optimal dose required for local control in this setting is unknown. METHODS AND MATERIALS:: @entity1 with unresectable or inoperable stage II/III @entity1149 with ECOG <=1 received 48 Gy in 20 daily fractions using intensity-modulated radiotherapy, followed by 1 of 3 boost dose levels: 16.8 Gy/7 (cumulative 2 Gy equivalent dose [EQD2]   76 Gy/38), 20.0 Gy/7 (EQD2   84 Gy/42), and 22.7 Gy/7 (EQD2   92 Gy/46). Two cycles of @entity900 / @entity2879 chemotherapy were given concurrent with RT. The maximum tolerated dose was defined as the dose at which >= 30% experienced dose-limiting @entity137 (any NCIC Common Terminology for Adverse Events V3.0 grade 3 or higher acute @entity137 ). RESULTS:: Twelve @entity1 completed treatment with a median follow-up of 22 months (range, 7 to 48). The median age was 72 (range, 54 to 80) and 50% of @entity1 had @entity420 . Five, 3, and 4 @entity1 were treated on dose levels 1, 2, and 3, respectively. No dose-limiting @entity137 was observed. One-year local progression-free survival and overall survival estimates were 81% and 58%, respectively. CONCLUSIONS:: Hypofractionated intensity-modulated radiotherapy was well tolerated and provided meaningful local control for @entity1 with locally advanced inoperable @entity1149 . The maximum tolerated dose of RT in this setting lies beyond an EQD2 of 92 Gy/46 and further dose escalation in this setting is warranted.

Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity1149 :: (MESH:D002289,Disease) :: ['Non-Small Cell Lung Cancer']
